Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Foa, E. B. Articles by Tu, X. Search for Related Content PubMed Citation Articles by Foa, E. B. Articles by Tu, X. Obsessive-Compulsive Disorder Behavior Therapy Cognitive Therapy Antidepressants

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder

OBJECTIVE: The purpose of the study was to test the relative and combined efficacy of clomipramine and exposure and ritual prevention in the treatment of obsessive-compulsive disorder (OCD) in adults. Serotonin reuptake inhibitors (SRIs) and cognitive behavior therapy by exposure and ritual prevention are both established treatments for OCD, yet their relative and combined efficacy have not been demonstrated conclusively. METHOD: A double-blind, randomized, placebo-controlled trial comparing exposure and ritual prevention, clomipramine, their combination (exposure and ritual prevention plus clomipramine), and pill placebo was conducted at one center expert in pharmacotherapy, another with expertise in exposure and ritual prevention, and a third with expertise in both modalities. Participants were adult outpatients (N=122 entrants) with OCD. Interventions included intensive exposure and ritual prevention for 4 weeks, followed by eight weekly maintenance sessions, and/or clomipramine administered for 12 weeks, with a maximum dose of 250 mg/day. The main outcome measures were the Yale-Brown Obsessive Compulsive Scale total score and response rates determined by the Clinical Global Impression improvement scale. RESULTS: At week 12, the effects of all active treatments were superior to placebo. The effect of exposure and ritual prevention did not differ from that of exposure and ritual prevention plus clomipramine, and both were superior to clomipramine only. Treated and completer response rates were, respectively, 62% and 86% for exposure and ritual prevention, 42% and 48% for clomipramine, 70% and 79% for exposure and ritual prevention plus clomipramine, and 8% and 10% for placebo. CONCLUSIONS: Clomipramine, exposure and ritual prevention, and their combination are all efficacious treatments for OCD. Intensive exposure and ritual prevention may be superior to clomipramine and, by implication, to monotherapy with the other SRIs.

This article has been cited by other articles:

				L. M. Christian and E. A. Storch Cognitive Behavioral Treatment of Postpartum Onset: Obsessive Compulsive Disorder With Aggressive Obsessions Clinical Case Studies, February 1, 2009; 8(1): 72 - 83. [Abstract] [PDF]

				H. B. Simpson, E. B. Foa, M. R. Liebowitz, D. R. Ledley, J. D. Huppert, S. Cahill, D. Vermes, A. B. Schmidt, E. Hembree, M. Franklin, et al. A Randomized, Controlled Trial of Cognitive-Behavioral Therapy for Augmenting Pharmacotherapy in Obsessive-Compulsive Disorder Am J Psychiatry, May 1, 2008; 165(5): 621 - 630. [Abstract] [Full Text] [PDF]

				B. O. Rothbaum Critical Parameters for D-Cycloserine Enhancement of Cognitive-Behaviorial Therapy for Obsessive-Compulsive Disorder Am J Psychiatry, March 1, 2008; 165(3): 293 - 296. [Full Text] [PDF]

				S. Wilhelm, U. Buhlmann, D. F. Tolin, S. A. Meunier, G. D. Pearlson, H. E. Reese, P. Cannistraro, M. A. Jenike, and S. L. Rauch Augmentation of Behavior Therapy With D-Cycloserine for Obsessive-Compulsive Disorder Am J Psychiatry, March 1, 2008; 165(3): 335 - 341. [Abstract] [Full Text] [PDF]

				K. R. Schruers Group cognitive behavioural therapy increases complete remission of obsessive-compulsive disorder symptoms compared with sertraline, but not response Evid. Based Ment. Health, February 1, 2007; 10(1): 25 - 25. [Full Text] [PDF]

				J. H. Greist and J. W. Jefferson Obsessive-Compulsive Disorder Focus, January 1, 2007; 5(3): 283 - 298. [Abstract] [Full Text] [PDF]

				M. T. Pato Ask the Expert: Obsessive-Compulsive Disorder Focus, January 1, 2007; 5(3): 314 - 315. [Full Text] [PDF]

				Bibliography for Obsessive-Compulsive Disorder Focus, January 1, 2007; 5(3): 328 - 329. [Full Text] [PDF]

				W. K. Goodman, E. A. Storch, G. R. Geffken, and T. K. Murphy Obsessive-Compulsive Disorder in Tourette Syndrome J Child Neurol, August 1, 2006; 21(8): 704 - 714. [Abstract] [PDF]

				E. G. Smith and A. Mathur Blinding in Psychotherapy Plus Medication Trials Am J Psychiatry, July 1, 2006; 163(7): 1295 - 1295. [Full Text] [PDF]

				J. F. Leckman and Y.-S. Kim A Primary Candidate Gene for Obsessive-compulsive Disorder. Arch Gen Psychiatry, July 1, 2006; 63(7): 717 - 720. [Full Text] [PDF]

				D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology J Psychopharmacol, November 1, 2005; 19(6): 567 - 596. [Abstract] [PDF]

				Combination Treatment for Obsessive-Compulsive Disorder Journal Watch Psychiatry, February 24, 2005; 2005(224): 6 - 6. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us